First external validation of the FLIPI‐L score in a single‐center series of patients with follicular lymphoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

First external validation of the FLIPI‐L score in a single‐center series of patients with follicular lymphoma

Published:2021-12-07 Issue: Volume: Page:
ISSN:0278-0232
Container-title:Hematological Oncology
language:en
Short-container-title:Hematological Oncology

Author:

Mozas Pablo¹^ORCID,Rivero Andrea¹,Rivas‐Delgado Alfredo¹,Correa Juan Gonzalo¹,Condom Maria¹,Nadeu Ferran²³,Giné Eva¹²³,Delgado Julio¹²³,Villamor Neus²³⁴,Campo Elías²³⁴⁵,Magnano Laura¹²³,López‐Guillermo Armando¹²³⁵

Affiliation:

1. Department of Haematology Hospital Clínic de Barcelona Barcelona Spain

2. Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) Barcelona Spain

3. Centro de Investigación Biomédica en Red de Cáncer (CIBERONC) Madrid Spain

4. Hematopathology Unit, Department of Pathology Hospital Clínic de Barcelona Barcelona Spain

5. Universitat de Barcelona Barcelona Spain

Funder

Instituto de Salud Carlos III

Fundación Española de Hematología y Hemoterapia

Publisher

Wiley

Subject

Cancer Research,Oncology,Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hon.2953

Reference17 articles.

1. WHO classification of tumours of haematopoietic and lymphoid tissues;Swerdlow S;WHO Classif Tumours,2017

2. Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study

3. Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study

4. Response duration and survival shorten after each relapse in patients with follicular lymphoma treated in the rituximab era

5. Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3